Kennedy, former FDA commissioner and Stanford president, dies of COVID-19

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Donald Kennedy, who served as FDA commissioner from 1977 to 1979, died this week of complications resulting from COVID-19. He was 88.

“I am sad to inform you of the passing of former FDA Commissioner Donald Kennedy, Ph.D., who passed away this week from complications resulting from COVID-19,” FDA Commissioner Stephen M. Hahn said in a statement. “Kennedy was a widely-recognized researcher, an admired teacher, an astute administrator, and a firm believer in the importance of public service. He leaves an impressive and inspirational legacy. Words cannot express enough how much we value the contributions Dr. Kennedy made to public health.

“As we all cope with this pandemic, his passing strikes close to home.

“Under his leadership, the agency warned the public about, and seized as an illegal drug, the popular but ineffective cancer treatment, Laetrile. He also led the agency as it faced widespread reaction to the attempted ban of saccharin under the Food Additives Amendment. Among his accomplishments, Dr. Kennedy implemented the 1976 Medical Device Amendments; pursued a concerted—though in the end unsuccessful—effort to pass a comprehensive Drug Regulation Reform Act (though many provisions of that effort eventually found their way into the law); proposed restrictions against the use of antibiotics in animal feed; and removed, under the Secretary’s order, the antidiabetic drug, phenformin, as an imminent hazard under the law—the first time that provision had been applied.”

After he left the FDA, Kennedy returned to Stanford University as vice president for academic affairs and provost and then, from 1980 to 1991, served as president. He served as editor-in-chief of the journal Science from 2000 to 2008.

Table of Contents

YOU MAY BE INTERESTED IN

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers. 

In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...

The Cancer Letter staff were finalists for nine 2025 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists—seven for journalism; two for design—and won first place for four. The Cancer Letter’s entries recognized by SPJ include investigative journalism, series, breaking news, features, photojournalism, commentary, illustration, and front page design. This is...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login